Neuromodulation News and Research

RSS

Greatbatch second quarter 2012 sales increase 14% to $166.5 million

Greatbatch, Inc., today announced results for its second quarter ended June 29, 2012.

26 Jul 2012

Neurotech’s ADNS-300 system obtains European CE Mark approval

Neurotech s.a., a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy.

7 Jun 2012

NYU Langone establishes unique neuromodulation center

The Department of Neurosurgery at NYU Langone Medical Center has established a unique, multidisciplinary neuromodulation center for the treatment of complex neurological conditions including movement disorders like Parkinson's disease, chronic pain and psychiatric condition such as obsessive compulsive disorder and severe depression.

31 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

AUA includes percutaneous tibial nerve stimulation in OAB treatment guidelines

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment.

22 May 2012

FDA clears Bioness smaller leg cuff for use with L300 Foot Drop System

Bioness Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a smaller leg cuff for use with the company's L300 Foot Drop System.

14 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Neurosurgeons from NYU Langone to present at AANS annual meeting

Neurosurgeons from NYU Langone Medical Center will present research and discuss surgical approaches and use of new technologies to treat neurosurgical conditions at the annual meeting of the American Association of Neurological Surgeons (AANS), held April 14-18, 2012 in Miami Beach, FL.

16 Apr 2012

Bioness commences StimRouter Neuromodulation System study for chronic peripheral nerve pain

Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.

9 Apr 2012

Patients with tinnitus may soon have a definitive therapy

Clinical trials of the new therapy, called Acoustic Coordinated Reset (ACR), have shown that it reduces the loudness and annoyance caused by tinnitus in seven out of 10 patients.

21 Mar 2012

Study tests new method of sound simulation for treating tinnitus

A new clinical trial is to test whether a pocket-sized device that uses sound simulation to reboot faulty 'wiring' in the brain could cure people with the debilitating hearing disorder tinnitus.

21 Mar 2012

SBMT announces 2012 recipients of Pioneers in Medicine, Technology and Healthcare Policy Awards

Today, the Society for Brain Mapping & Therapeutics announced the 2012 recipients of the organization's prestigious Pioneers in Medicine, Technology, and Healthcare Policy Awards.

17 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

$Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy$

Health Canada grants license to Medtronic DBS Therapy for refractory epilepsy

Medtronic, Inc. today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients.

From Medtronic 16 Mar 2012

ROSETTA Study to compare two therapies in women with overactive bladder

Overactive bladder, or the sudden urge to urinate, affects the quality of life of many women. Studies have shown that not all women respond to or can tolerate oral medications and may benefit from other therapies.

1 Mar 2012

Tenfold increase in OARnet network bandwidth speeds will boost medical research

Following his State of the State announcement of a tenfold boost to OARnet's statewide network bandwidth, Governor John R. Kasich joined medical researchers from across the state on Feb. 27 in a video teleconference to discuss how the faster network speeds will help enhance innovation.

29 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012

Greatbatch acquires NeuroNexus

Greatbatch, Inc., today announced the acquisition of NeuroNexus Technologies for approximately $12 million in cash, including the assumption of debt and future considerations.

17 Feb 2012

St. Jude Medical fourth quarter net sales increase 4% to $1.407B

St. Jude Medical, Inc. today reported sales and net earnings for the fourth quarter and year ended December 31, 2011.

25 Jan 2012

DBS safe and effective for patients with advanced Parkinson's

Researchers from the University of Florida and 14 additional medical centers reported results today in the online version of The Lancet Neurology journal indicating that deep brain stimulation - also known as DBS - is effective at improving motor symptoms and quality of life in patients with advanced Parkinson's disease.

12 Jan 2012